Skip to content

Combined Effect of tDCS and Motor or Cognitive Activity in Patients With Alzheimer's Disease

Combined Effect of tDCS and Motor or Cognitive Activity in Patients With Alzheimer's Disease: A Proof-of-Concept Pilot Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06619795
Enrollment
23
Registered
2024-10-01
Start date
2018-06-01
Completion date
2019-12-31
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease (AD)

Keywords

Transcranial Direct Current Stimulation, Motor Activity, Cognitive Stimulation, Alzheimer's disease

Brief summary

The goal of this clinical trial is to evaluate the effectiveness of combining tDCS with motor or cognitive activities on cognitive functions in patients with AD. Second aim is to investigate if tDCS has a different impact if it is combined with motor or cognitive activities.

Interventions

DEVICEAnodal tDCS

In addition to anodal tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.

DEVICESham tDCS

In addition to Sham tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.

Sponsors

Universita di Verona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Mini Mental State Examination (MMSE) major or equal to 15; * good level of compliance; * acetylcholinesterase inhibitor treatment (e.g., donepezil, rivastigmine); * no modifications of medication during the last four months.

Exclusion criteria

* behavioral disorders (e.g., aggressiveness); * alcohol abuse; * orthopedic pathology with risk of falls to the ground; * respiratory pathology; * severe auditory or visual deficits uncorrected; * history of epileptic fits; * anti-epileptic medication; * metallic body implants; pacemaker; * psychiatric, neurologic, systemic or metabolic disorders.

Design outcomes

Primary

MeasureTime frameDescription
Mini Mental State Examination (MMSE)From enrollment to the end of treatment at two weeks(Range: 0-30; higher score=best performance).

Secondary

MeasureTime frameDescription
Digit Span Test- Forward (DSF)From enrollment to the end of treatment at two weeksDigit Span Test- Forward (DSF), used to measure span of immediate verbal recall. The examiner presents digits verbally at a rate of one per second. Examiner requires the participant to repeat the digits in the same order. The number of digits increases by one until the participant consecutively fails two trials of the same digit span length (higher score=best performance)
Digit Span Test- Backward (DSB)From enrollment to the end of treatment at two weeksDigit Span Test- Backward (DSB), used to measure working memory. The examiner presents digits verbally and repeats the digits in reverse order. The number of digits increases by one until the participant consecutively fails two trials of the same digit span length (higher score=best performance).
Phonemic Fluency Test (PFT)From enrollment to the end of treatment at two weeksPhonemic Fluency Test (PFT), used to measure processing speed, language production and executive functions. Participants are given one minute to produce as many unique words as possible starting with a given letter. The participant's score in each task is given by the number of correct words (higher score=best performance).
Picture Recognition (PR)From enrollment to the end of treatment at two weeksPicture Recognition (PR) is a subtest of the Rivermead Behavioral Memory Test-3, an ecological memory battery resembling everyday tasks, with the aim to measure daily memory function. The examinee is shown a set of picture and then is asked to recognize them from a further set of pictures at a later time in the testing session. It has two parallel version for monitoring changes over time (Range: 0-15; higher score=best performance).
Sustained Attention to Response Test (SART)From enrollment to the end of treatment at two weeksSustained Attention to Response Test (SART): used to evaluate sustained attention and control inhibition. In the test, participants view a computer monitor on which a random series of single digits are presented at the regular rate of 1 per 1.15 seconds. The task is to press a single response key following each presentation with the exception of a nominated no-go digit, to which no response should be made. In the standard version of the test, 225 digits are presented in a continuous sequence over 4.3 minutes. The outcomes are false allarm (FA), omission (OM) and reaction times (RT) (higher score = worst performance)
Neuropsychiatric Inventory (NPI)From enrollment to the end of treatment at two weeksNeuropsychiatric Inventory (NPI) to evaluate the presence, frequency and severity of behavioral disorders (Range 0-144; higher score = worst performance).
Visual Search Test (VST)From enrollment to the end of treatment at two weeksVisual Search Test (VST), to assess visual-selective attention. Three matrices are shown to the subject and the patients has to cross in 45 minutes the target stimuli between distractors (Range: 0-60; higher score=best performance).

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026